Fig. 1

This graph shows factor VIII inhibitor activity and factor VIII coagulant activity levels. The patient was treated with recombinant activated factor VII and activated prothrombin complex concentrate for 18 days. He was also given rituximab weekly for four administrations and one cycle of azacytidine, then factor VIII inhibitor disappeared and factor VIII coagulant activity gradually returned to normal. 5-AZA azacytidine, AAFVIII factor VIII inhibitor, aPCC activated prothrombin complex concentrate, VIII: C factor VIII coagulant activity